Jones Lang LaSalle (NYSE:JLL) slides 2.9% after William Blair analyst Stephen Sheldon describes the firm's transaction outlook as "murky" and says it may not improve until a health resolution such as a vaccine becomes available.

Management said deal timelines remain extended and some decisions continue to be delayed.

JLL stock fell as much as 5.4% in trading during the session, its biggest intraday drop in more than a month.

Now assumes Q4 fee revenue will fall 21% Y/Y vs. 22%-24% in the previous two quarters.

READ FULL ARTICLE HERE